期刊
LEUKEMIA & LYMPHOMA
卷 52, 期 10, 页码 1999-2006出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2011.591012
关键词
Flavopiridol; acute myeloid leukemia; BCL-2; HMGA1; STAT3; E2F1
资金
- NIH [RO1 CA092339]
- Leukemia & Lymphoma Scholar Award [1694-06]
- Alex's Lemonade Stand Foundation
- Maryland Stem Cell Research Fund
- J. P. McCarthy Foundation
- NCI [U01 CA70095]
- NCI Cancer Center [P30 069773-45]
- Prevent Cancer Foundation
Flavopiridol is a cyclin-dependent kinase inhibitor that induces cell cycle arrest, apoptosis, and clinical responses in selected patients with acute myeloid leukemia (AML). A better understanding of the molecular pathways targeted by flavopiridol is needed to design optimal combinatorial therapy. Here, we report that in vivo administration of flavopiridol induced expression of the BCL-2 anti-apoptotic gene in leukemic blasts from adult patients with refractory AML. Moreover, flavopiridol repressed the expression of genes encoding oncogenic transcription factors (HMGA1, STAT3, E2F1) and the major subunit of RNA Polymerase II. Our results provide mechanistic insight into the cellular pathways targeted by flavopiridol. Although further studies are needed, our findings also suggest that blocking anti-apoptotic pathways could enhance cytotoxicity with flavopiridol.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据